Author(s)
Shyamapada Mandal
Published 5 Projects
COVID-19 SARS-CoV-2 Epidemiology Infectious Diseases Key Words
Content
Due to non-availability of specific therapeutics against COVID-19, repurposing of approved drugs is a reasonable option. Cytokines imbalance in COVID-19 resembles cancer; exploration of anti-inflammatory agents, might reduce COVID-19 mortality. The current study investigates the effect of ruxolitinib treatment in SARS-CoV-2 infected alveolar cells compared to the uninfected one from the GSE5147507 dataset. The protein-protein interaction network, biological process and functional enrichment of differentially expressed genes were studied using STRING App of the Cytoscape software and R programming tools. The present study indicated that ruxolitinib treatment elicited similar response equivalent to that of SARS-CoV-2 uninfected situation by inducing defense response in host against virus infection by RLR and NOD like receptor pathways. Further, the effect of ruxolitinib in SARS-CoV-2 infection was mainly caused by significant suppression of IFIH1, IRF7 and MX1 genes as well as inhibition of DDX58/IFIH1-mediated induction of interferon-I and -II signalling.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 2 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 2 years ago
Jignesh H. Parmar
0 views • 2 years ago
Winston A. Haynes
0 views • 2 years ago
Noam Mazor
0 views • 2 years ago
Global Immunotalks
182 views • 2 years ago
Cem Yuksel
345 views • 2 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Shyamapada Mandal. (2021, Nov 9).Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy[Video]. Scitok. https://scitok.com/project/p/ccd5861e
Mandal Manisha. "Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy" Scitok, uploaded by Mandal Shyamapada, 9 Nov, 2021, https://scitok.com/project/pccd5861e
Shyamapada Mandal. "Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy" Scitok. (Nov 9, 2021). https://scitok.com/project/p/ccd5861e
Shyamapada Mandal (Nov 9, 2021). Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy Scitok. https://scitok.com/project/p/ccd5861e
Shyamapada Mandal. Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy[video]. 2021 Nov 9. https://scitok.com/project/p/ccd5861e
@online{al2006link, title={ Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy }, author={ Mandal, Shyamapada }, organization={Scitok}, month={ Nov }, day={ 9 }, year={ 2021 }, url = {https://scitok.com/project/p/ccd5861e}, }